A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy (NIVORAD)
Latest Information Update: 18 Apr 2022
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NIVORAD
- Sponsors Bristol-Myers Squibb
- 11 Jul 2019 Status changed from recruiting to discontinued.
- 06 Jun 2017 According to trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology, two out of 20 sites are open for enrollment as of Feb 2017
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology